This HTML5 document contains 123 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00153/identifier/wikipedia/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00153/identifier/pharmgkb/
foafhttp://xmlns.com/foaf/0.1/
n26http://linked.opendata.cz/resource/mesh/concept/
n16http://linked.opendata.cz/resource/drugbank/company/
n10http://linked.opendata.cz/resource/drugbank/drug/DB00153/identifier/kegg-compound/
n15http://linked.opendata.cz/resource/drugbank/dosage/
n4http://linked.opendata.cz/resource/drugbank/mixture/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00153/identifier/pubchem-compound/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00153/identifier/pubchem-substance/
n20http://bio2rdf.org/drugbank:
n31http://linked.opendata.cz/resource/drugbank/drug/DB00153/identifier/kegg-drug/
n29http://linked.opendata.cz/resource/drugbank/drug/DB00153/identifier/drugbank/
admshttp://www.w3.org/ns/adms#
n22http://www.rxlist.com/cgi/generic/
n7http://linked.opendata.cz/resource/drugbank/drug/DB00153/identifier/national-drug-code-directory/
n9http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n21http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n19http://www.pdrhealth.com/drug_info/nmdrugprofiles/nutsupdrugs/
n25http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n27http://www.drugs.com/cdi/
n28http://linked.opendata.cz/resource/drugbank/drug/DB00153/identifier/chemspider/
n5http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n30http://linked.opendata.cz/resource/drugbank/drug/DB00153/identifier/chebi/
n24http://linked.opendata.cz/resource/atc/
n23http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00153
rdf:type
n3:Drug
n3:description
Ergocalciferol (Vitamin D2) is a derivative of ergosterol formed by ultraviolet rays breaking of the C9-C10 bond. It differs from cholecalciferol in having a double bond between C22 and C23 and a methyl group at C24. [PubChem]
n3:dosage
n15:271B4CC4-363D-11E5-9242-09173F13E4C5 n15:271B4CC5-363D-11E5-9242-09173F13E4C5 n15:271B4CC6-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# DeLuca HF: Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr. 2004 Dec;80(6 Suppl):1689S-96S. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15585789
n3:group
approved nutraceutical
n3:halfLife
19 to 48 hours (however, stored in fat deposits in body for prolonged periods).
n3:indication
For use in the management of hypocalcemia and its clinical manifestations in patients with hypoparathyroidism, as well as for the treatment of familial hypophosphatemia (vitamin D resistant rickets). This drug has also been used in the treatment of nutritional rickets or osteomalacia, vitamin D dependent rickets, rickets or osteomalacia secondary to long-term high dose anticonvulsant therapy, early renal osteodystrophy, osteoporosis (in conjunction with calcium), and hypophosphatemia associated with Fanconi syndrome (with treatment of acidosis).
n3:manufacturer
n16:271B4CB9-363D-11E5-9242-09173F13E4C5 n16:271B4CBA-363D-11E5-9242-09173F13E4C5 n16:271B4CB7-363D-11E5-9242-09173F13E4C5 n16:271B4CB8-363D-11E5-9242-09173F13E4C5 n16:271B4CBB-363D-11E5-9242-09173F13E4C5 n16:271B4CBC-363D-11E5-9242-09173F13E4C5 n16:271B4CB1-363D-11E5-9242-09173F13E4C5 n16:271B4CB2-363D-11E5-9242-09173F13E4C5 n16:271B4CB0-363D-11E5-9242-09173F13E4C5 n16:271B4CB5-363D-11E5-9242-09173F13E4C5 n16:271B4CB6-363D-11E5-9242-09173F13E4C5 n16:271B4CB3-363D-11E5-9242-09173F13E4C5 n16:271B4CB4-363D-11E5-9242-09173F13E4C5
owl:sameAs
n9:DB00153 n20:DB00153
dcterms:title
Ergocalciferol
adms:identifier
n7:51991-604-01 n10:C05441 n11:46505053 n12:PA449484 n13:5280793 n14:Ergocalciferol n28:4444351 n29:DB00153 n30:28934 n31:D00187
n3:mechanismOfAction
Activated ergocalciferol increases serum calcium and phosphate concentrations, primarily by increasing intestinal absorption of calcium and phosphate through binding to a specific receptor in the mucosal cytoplasm of the intestine. Subsequently, calcium is absorbed through formation of a calcium-binding protein. 25-hydroxyergocalciferol is the intermediary metabolite of ergocalciferol. Although this metabolite exhibits 2–5 times more activity than unactivated ergocalciferol in curing rickets and inducing calcium absorption and mobilization (from bone) in animals, this increased activity is still insufficient to affect these functions at physiologic concentrations. Activated ergocalciferol stimulate resorption of bone and are required for normal mineralization of bone. Physiological doses of ergocalciferol also promotes calcium reabsorption by the kidneys, but the significance of this effect is not known.
n3:packager
n16:271B4CA5-363D-11E5-9242-09173F13E4C5 n16:271B4CA6-363D-11E5-9242-09173F13E4C5 n16:271B4CA3-363D-11E5-9242-09173F13E4C5 n16:271B4CA4-363D-11E5-9242-09173F13E4C5 n16:271B4CA1-363D-11E5-9242-09173F13E4C5 n16:271B4CA2-363D-11E5-9242-09173F13E4C5 n16:271B4CA0-363D-11E5-9242-09173F13E4C5 n16:271B4CAF-363D-11E5-9242-09173F13E4C5 n16:271B4CAD-363D-11E5-9242-09173F13E4C5 n16:271B4CAE-363D-11E5-9242-09173F13E4C5 n16:271B4CAB-363D-11E5-9242-09173F13E4C5 n16:271B4CAC-363D-11E5-9242-09173F13E4C5 n16:271B4CA9-363D-11E5-9242-09173F13E4C5 n16:271B4CAA-363D-11E5-9242-09173F13E4C5 n16:271B4CA7-363D-11E5-9242-09173F13E4C5 n16:271B4CA8-363D-11E5-9242-09173F13E4C5
n3:synonym
Oleovitamin D2 Ercalciol Vitamina D2 (5Z,7e,22e)-(3S)-9,10-Seco-5,7,10(19),22-ergostatetraen-3-ol Ergocalciferol Activated ergosterol Viosterol (3beta,5Z,7e,22e)-9,10-Secoergosta-5,7,10(19),22-tetraen-3-ol Ergocalciferolum Vitamin D2 Calciferol (5Z,7e,22e)-(3S)-9,10-Secoergosta-5,7,10(19),22-tetraen-3-ol
n3:toxicity
LD<sub>50</sub> = 23.7 mg/kg (Orally in mice); LD<sub>50</sub> = 10 mg/kg (Orally in rats ); Nausea, vomiting and diarrhea, weight loss, irritability, weakness, fatigue, lassitude, and headache.
n3:mixture
n4:271B4C97-363D-11E5-9242-09173F13E4C5 n4:271B4C98-363D-11E5-9242-09173F13E4C5 n4:271B4C96-363D-11E5-9242-09173F13E4C5 n4:271B4C9B-363D-11E5-9242-09173F13E4C5 n4:271B4C9C-363D-11E5-9242-09173F13E4C5 n4:271B4C99-363D-11E5-9242-09173F13E4C5 n4:271B4C9A-363D-11E5-9242-09173F13E4C5 n4:271B4C9F-363D-11E5-9242-09173F13E4C5 n4:271B4C9D-363D-11E5-9242-09173F13E4C5 n4:271B4C9E-363D-11E5-9242-09173F13E4C5
n3:proteinBinding
>99.8%
n3:synthesisReference
Charles W. Bishop, Glenville Jones, Ronald L. Horst, Nicholas J. Koszewski, Joyce C. Knutson, Raju Penmasta, Robert M. Moriarty, Stephen Strugnell, Timothy A. Reinhardt, Liang Guo, Sanjay K. Singhal, Lei Zhao, "Methods for preparation and use of 1A,24(S)-dihydroxy vitamin D2." U.S. Patent US5789397, issued March, 1992.
n25:hasConcept
n26:M0007650
foaf:page
n19:vit_0265.shtml n22:ergocalciferol.htm n27:ergocalciferol.html
n3:IUPAC-Name
n5:271B4CCB-363D-11E5-9242-09173F13E4C5
n3:InChI
n5:271B4CD1-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n5:271B4CD0-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n5:271B4CCD-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n5:271B4CCE-363D-11E5-9242-09173F13E4C5
n3:SMILES
n5:271B4CCF-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n5:271B4CE1-363D-11E5-9242-09173F13E4C5 n5:271B4CC9-363D-11E5-9242-09173F13E4C5
n3:logP
n5:271B4CC7-363D-11E5-9242-09173F13E4C5 n5:271B4CE3-363D-11E5-9242-09173F13E4C5 n5:271B4CCA-363D-11E5-9242-09173F13E4C5
n3:logS
n5:271B4CC8-363D-11E5-9242-09173F13E4C5
n23:hasATCCode
n24:A11CC01
n3:H-Bond-Acceptor-Count
n5:271B4CD7-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n5:271B4CD8-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n5:271B4CD2-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n5:271B4CD3-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n5:271B4CD5-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n5:271B4CD4-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n5:271B4CD6-363D-11E5-9242-09173F13E4C5
n3:absorption
Readily absorbed from small intestine (proximal or distal), requires presence of bile salts.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
50-14-6
n3:category
n3:containedIn
n21:271B4CC1-363D-11E5-9242-09173F13E4C5 n21:271B4CC2-363D-11E5-9242-09173F13E4C5 n21:271B4CBF-363D-11E5-9242-09173F13E4C5 n21:271B4CC0-363D-11E5-9242-09173F13E4C5 n21:271B4CBD-363D-11E5-9242-09173F13E4C5 n21:271B4CBE-363D-11E5-9242-09173F13E4C5 n21:271B4CC3-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n5:271B4CDD-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n5:271B4CDF-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n5:271B4CE0-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n5:271B4CE2-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n5:271B4CDC-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n5:271B4CDB-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n5:271B4CDE-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n5:271B4CCC-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n5:271B4CD9-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n5:271B4CDA-363D-11E5-9242-09173F13E4C5